image credit: Freepik

FDA authorises the first AI-based software to detect prostate cancer

October 6, 2021


On 21 September, the US Food and Drug Administration (FDA) authorised Paige Prostate, the first artificial intelligence (AI) based software designed to detect areas at risk of being cancerous in prostate biopsy images. This software allows pathologists to make a higher number of accurate diagnoses of cancerous tissues, which could help address the growing number of cancer cases worldwide.

Prostate cancer is a cancer that develops in the prostate, a male gland responsible for producing a fluid that nourishes and transports semen. According to the US Centres for Disease Control and Prevention (CDC), prostate cancer is the most common cancer in men in the US, aside from skin cancers.